[go: up one dir, main page]

EP0300030A1 - Menschliche proteine mit blutgerinnungs- und entzündungshemmender wirkung - Google Patents

Menschliche proteine mit blutgerinnungs- und entzündungshemmender wirkung

Info

Publication number
EP0300030A1
EP0300030A1 EP88902031A EP88902031A EP0300030A1 EP 0300030 A1 EP0300030 A1 EP 0300030A1 EP 88902031 A EP88902031 A EP 88902031A EP 88902031 A EP88902031 A EP 88902031A EP 0300030 A1 EP0300030 A1 EP 0300030A1
Authority
EP
European Patent Office
Prior art keywords
protein
pap
fraction
exchange chromatography
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88902031A
Other languages
English (en)
French (fr)
Inventor
Kazuo Fujikawa
Meher H. Irani
Bruce L. A. Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Zymogenetics Inc
Original Assignee
University of Washington
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Zymogenetics Inc filed Critical University of Washington
Publication of EP0300030A1 publication Critical patent/EP0300030A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to the production and use of proteins in general, and more specifically, to the production of novel proteins exhibiting anticoagulant and anti-inflammatory activity, DNA sequences encoding these proteins, and the use of these proteins in warm ⁇ blooded animals.
  • Blood coagulation is a process consisting of a complex interaction of various blood components or factors which eventually gives rise to a fibrin clot.
  • the blood components which participate in what has been referred to as the coagulation "cascade” are proenzymes or zymogens, enzymatically inactive proteins which are converted to proteolytic enzymes by the action of an acti ⁇ vator, itself an activated clotting factor.
  • Coagulation factors which have undergone such a conversion are gener ⁇ ally referred to as “active factors,” and are designated by the addition of a lower case postscript "a” (e.g., factor Vila) .
  • Intrinsic and the “extrinsic coagulation pathways” refers to those reactions which lead to thrombin formation through utilization of factors present only in plasma.
  • An intermediate event in the intrinsic pathway is the activation of factor IX to factor IXa, a reaction catalyzed by factor XIa and calcium ions.
  • Factor IXa then participates in the activation of factor X in the presence of factor Villa, phospholipid, and calcium ions.
  • the "extrinsic pathway” involves plasma factors, and additionally involves components present in tissue extracts.
  • Factor VII one of the proenzymes referred to above, participates in the extrinsic pathway of blood coagu ⁇ lation by converting (upon its activation to Vila) factor X to Xa in the presence of tissue factor and calcium ions.
  • Factor Xa in turn converts prothrombin to thrombin in the presence of factor Va, calcium ions, and. phospholipid.
  • kidney dialysis, deep vein thrombosis, and disseminated intravascular coagu ⁇ lation (DIC) it is necessary to block the coagulation cascade through the use of anticoagulants, such as heparin, coumarin, derivatives of coumarin, indandione derivatives, or other agents.
  • anticoagulants such as heparin, coumarin, derivatives of coumarin, indandione derivatives, or other agents.
  • a heparin treatment or an extracorporeal treatment with citrate ion U.S. Patent 4,500,309
  • Heparin is also used in preventing deep vein thrombosis in patients undergoing surgery. Treatment with low doses of heparin may, however, cause heavy bleeding.
  • heparin has a half-life of approximately 80 minutes, it is rapidly cleared from the blood. Because heparin acts as a cofactor for antithrombin III (AT III) , and antithrombin III is rapidly depleted in DIC treatment, it is often difficult to maintain the proper heparin dosage, necessitating continuous monitoring of AT III and heparin levels. Heparin is also ineffective if AT III depletion is extreme. Further, prolonged use of heparin may also increase platelet aggregation and reduce platelet count, and has been implicated in the development of osteoporosis. Indandione derivatives may also have toxic side effects.
  • AT III antithrombin III
  • compositions dis- closed within the art which are alleged to have anticoagu ⁇ lant activity.
  • One such composition is disclosed by Reutelingsperger et al. (Eur. J. Biochem. 151: 625-629, 1985), who isolated a 32,000 dalton polypeptide from human umbilical cord arteries.
  • Another composition is disclosed by arn-Cramer et al. (Circulation Suppl, part 2, 74; 2-408U, Abstract #1630, 1986). They detected a factor Vila inhibitor Of an apparent molecular weight of 34,500 in plasma.
  • the present invention discloses novel proteins which have therapeutic potential as both anticoagulants and as anti-inflammatory agents.
  • the present invention discloses the heretofore unrecognized use of lipocortins in reducing blood coagula ⁇ tion in warm-blooded animals.
  • the novel proteins generally have the following properties: (a) they bind to phospholipids; (b) they inhibit phospholipase A2 (c) they bind to anion-exchange chromatographic media? and (d) they exhibit anticoagulant activity. In addition, the proteins also exhibit anti-inflammatory activity.
  • the proteins generally have the following properties: (a) they bind to phospholipids; (b) they inhibit phospholipase A2?
  • the proteins generally have the following properties: (a) they bind to phospholipids; (b) they inhibit phospho ⁇ lipase A2; (c) they do not bind to DEAE-Sepharose at pH 5 to pH 9 and a salt concentration above about 75 mM; and (d) they exhibit anticoagulant activity. In addition, the proteins also exhibit anti-inflammatory activity.
  • a related aspect of the present invention is directed toward a method for producing a representative protein exhibiting anticoagulant activity from a biological fluid.
  • Suitable biological fluids include aqueous extracts of highly vascularized tissue and cell lysates.
  • the method generally comprises (a) adding ammonium sulfate to the biological fluid to approximately 20% to 50% saturation to form a first precipitate and a supernatant; (b) adding ammonium sulfate to the supernatant to at least approximately 60% saturation to form a second precipitate; (c) isolating the second precipitate and dissolving the second precipitate in a suitable buffer to form a solution; (d) reducing the salt concentration of the solution such that the reduced solution can be fractionated by anion-exchange chromatography; (e) fractionating the reduced solution by anion-exchange chromatography to produce an adsorbed fraction and a non-adsorbed fraction.
  • the adsorbed fraction is further fractionated by gel filtration to produce an enriched fraction, subsequently reducing the salt concentration of the enriched fraction such that the reduced fraction can be fractionated by cation-exchange chroma tography, and then further fractionating the reduced fraction by cation-exchange chromatography to separate the protein having anticoagulant activity from the reduced fraction.
  • the method may also include, after the step of fractionating the reduced solution, concentrating the adsorbed fraction. It is preferred that buffers and other solutions used within the method contain a chela ting agent, such as EDTA.
  • the non-adsorbed fraction is further fractionated by gel filtration to produce an enriched fraction, the salt concentration of the enriched fraction is subsequently reduced such that the reduced fraction can be fractionated by cation-exchange chromatography, and then the reduced fraction is further fractionated by cation-exchange chromatography to separate the protein having anticoagulant activity from the reduced fraction.
  • the method may also include, after the step of fractionating the reduced solution, concentrating the non-adsorbed fraction.
  • compositions comprising an effective amount of one of the proteins described herein in combination with a physiologically acceptable carrier or diluent are also disclosed.
  • suitable carriers or diluents include sterile water and physiological saline.
  • the pharma ⁇ ceutical compositions are particularly useful in reducing blood coagulation in warm-blooded animals as well as reducing inflammation in warm-blooded animals.
  • lipocortins including lipocortin I and lipocortin II, may be used within a method for reducing blood coagulation in warm-blooded animals.
  • the method generally comprises administering to a warm-blooded animal an effective amount of the lipocortin in combination with a physiologically acceptable carrier or diluent.
  • the present invention discloses purified DNA sequences encoding the proteins described above. Host cells transfected or transformed with an expression vector containing these DNA sequences are also disclosed. Other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings.
  • Figure 1 illustrates an elution profile of a
  • DEAE-Sepharose column The bar indicates pooled fractions used for subsequent purification of two representative proteins of the present invention.
  • Figure 2 illustrates an elution profile of a Sephadex G-75 gel filtration column. The bar indicates fractions pqoled for subsequent purification steps.
  • Figure 3 illustrates chromatography of a represen ⁇ tative PAP-I protein of the present invention on a Mono-S column. The protein is eluted from the column at approximately 12% buffer D.
  • FIG. 4 illustrates SDS-polyacrylamide gel electrophoresis patterns of purified proteins having anticoagulant and anti-inflammatory activity.
  • Lane 1 SDS-polyacrylamide gel electrophoresis patterns of purified proteins having anticoagulant and anti-inflammatory activity.
  • Figure 5 illustrates the amino acid sequences of PAP-I, li ⁇ ocortin-I and the partial amino acid sequences of PAP-II, PAP-III and PAP-IV. Regions of amino acid identity are boxed. Tentatively-identified methionine residues are designated by a lower-case m. Unidentified residues are designated by an upper-case X.
  • Figure 6 illustrates the elution profile of PAP-II from a Mono S column.
  • Figure 7 illustrates the elution profile of PAP-III and PAP-IV from a Mono S column.
  • Figure 8 shows the cDNA sequence encoding PAP-I and the amino acid sequence deduced from the cDNA sequence.
  • the amino-terminal methionine residue, designated (M) is removed from the mature protein after translation.
  • Figure 9 illustrates the construction of an ADH2-42 promoter.
  • Figure 10 illustrates the construction of expression vectors containing the PAP-I cDNA.
  • FIG. 11 illustrates the subcloning of the TPI1 terminator.
  • Anticoagulant activity is defined as the ability to inhibit blood coagulation.
  • blood coagulation is a complex process involving the interaction of various elements, including enzymes, cofactors, ions and phospholipids. Compounds exhibiting anticoagulant activity may exert this activity by interfering with any of these elements.
  • heparin interferes with the action of factor Xa by acceler ⁇ ating the formation of complexes between antithrombin III, thrombin and factor Xa; while protein C, a blood protein, exerts its anticoagulant activity by inactivating factors Va and Villa.
  • reducing blood coagulation shall include reducing or preventing coagulation in vivo by any mechanism.
  • Anticoagulant activity is assayed in an in vitro clotting assay, such as the kaolin-induced clot- ting assay or the thromboplastin-induced clotting assay.
  • an in vitro clotting assay such as the kaolin-induced clot- ting assay or the thromboplastin-induced clotting assay.
  • a compound is said to exhibit anticoagulant activity when its addition to such an assay system results in delayed clotting, such as delayed fibrin generation.
  • Anti-inflammatory activity is the ability to interfere with the inflammatory process, thereby reducing or eliminating any or all of the symptoms of inflammation. According to current understand ⁇ ing, anti-inflammatory activity is typically the result of interference with the production of prostaglandins and/or leukotrienes, compounds which appear to be major physiologi ⁇ cal mediators of inflammation.
  • a key step in the inflamma ⁇ tion process is the generation of ara ⁇ hidonic acid from phospholipids by phospholipase A - Compounds which inhibit the action of phospholipase A2, for example, by binding to phospholipids, will exhibit anti-inflammatory activity.
  • a compound will be recognized as exhibiting anti-inflammatory activity if it inhibits phospholipase A2 or otherwise interferes with prostaglandin synthesis.
  • Assay systems for anti-inflamma- tory activity are known in the art.
  • Biological fluid A liquid containing cells, portions of cells or cell products.
  • Biological fluids include, but are not limited to, tissue homogenates, tissue extracts, blood, plasma, serum, cell lysates and cell-conditioned culture media.
  • Phospholipids are a class of compounds consisting of fatty acid molecules esterified to the first and second hydroxyl groups of glycerol, with the third hydroxyl group of the glycerol moiety esterified to phosphoric acid. Phospholipids occur in cell membranes and, as noted above, contribute to both blood coagulation and inflammation. For example, prothrombin and factor Xa bind to membrane phospholipids, resulting in the activation of prothrombin to thrombin.
  • the phrase "binds to phospholipid” shall mean binding to phospholipid vesicles prepared from rabbit brain cephalin (a mixture of neutral and acidic phospholipid) or a mixture of phosphatidylserine:phosphatidylcholine (molar ratio 20:80) in a standard assay system.
  • Phospholipase A? As noted above, phospholipase A2 is an enzyme which cleaves certain phospholipids to release arachidonic acid, a precursor of prostaglandins and leukotrienes. As used herein, “inhibition of phospholipase A2" refers specifically to inhibiting the production of arachidonic acid by phospholipase A2, typically by binding to the phospholipid substrate.
  • Complementary DNA or cDNA ⁇ A DNA molecule or sequence which has been enzymatically synthesized from the sequences present in an mRNA template, or a clone of such a molecule.
  • DNA construct A DNA molecule, or a clone of such a molecule, either single or double-stranded, which has been modified through human intervention to contain segments of DNA combined and juxtaposed in a manner which would not otherwise exist in nature.
  • Another representative protein of the present invention has been found to have the following character- istics.
  • the anticoagulant activity of the proteins described herein is believed to be due to their ability to bind to phospholipid. Accordingly, any activation step in the coagulation cascade that requires phospholipid may be inhibited by these proteins.
  • prothrombin by factor Xa
  • other phospholipid-dependent reactions including the activation of factor X by com ⁇ plexes of factor IXa-phospholipid-Ca ++ -factor Villa, or the activation of factor X by complexes of factor VIIa-Ca ++ -tissue factor, would be expected to be inhibited by these proteins.
  • the proteins of the present invention would be expected to inhibit the inactivation of factors Villa and Va by activated protein C.
  • the proteins described herein inhibit the clotting factors without inactivating them.
  • the use of these novel proteins may therefore be preferred in certain instances where it is desirable to maintain partial functioning of the coagulation system, thereby preventing severe bleeding from occurring.
  • At least some of the novel proteins described herein have been found to be highly homologous to the lipocortin family of proteins.
  • the lipocortins have the following common features: (1) they ..have an inhibitory activity against phospholipase A2 and inhibit the prosta- glandin-leukotriene- ediated inflammatory response by blocking arachidonic acid synthesis; (2) their synthesis is stimulated by anti-inflammatory drugs, such as gluco- corticoid and dexamethasone; and (3) they are the prime substrates of EGF receptor/tyrosine kinases or protein serine-threonine kinases.
  • Lipocortins although they have different names, have been detected or isolated from human placenta, chicken embryo fibroblasts, columnar epithelial cells of intestine, guinea pig lung, and other cells. Molecular weights of lipocortins generally range between 34,000 and 38,000. The sequences of the only well-characterized lipocortins, lipo ⁇ cortin I and II, have been determined by cDNA sequencing. Lipocortin I and II were shown to contain over 50% sequence identity and to be composed of four repeated sequences. Each repeat has putative Ca ++ -dependent phospholipid bind ⁇ ing sites. Lipocortin I and lipocortin II may be prepared by the method of Huang et al.
  • Suitable media include DEAE-Sephadex, DEAE-cellulose, DEAE-Sepharose, QAE-Sephadex, and QAE-Sepharose.
  • This difference reflects distinct structural characteristics, that is, differences in amino acid sequences.
  • the capacity to bind in this manner requires either an overall negative charge or exposed areas of negative charge capable of participating in binding.
  • lipocortin I may contain two disulfide bonds, because lipocortin I contains four cysteinyl residues as determined by cDNA sequencing.
  • the proteins of the present invention may be substituted for heparin or other traditional anticoagulants in the treatment of disseminated intravascular coagulation, deep vein thrombosis, or other conditions requiring anti ⁇ coagulant therapy. It is preferable to administer the pro ⁇ teins of the present invention in an intravenous infusion in combination with a physiologically acceptable carrier or diluent.
  • Therapeutic compositions may be formulated in accordance with routine procedures. Typically, such compositions will comprise a solution in sterile water or physiological saline. They may further comprise adjuvants, stabilizers or other diluents. A local anesthetic to relieve pain at the site of infusion may also be included.
  • compositions of the present inven ⁇ tion for use as anticoagulants will preferably be provided in an infusion bottle labeled to indicate the level of anticoagulant activity present.
  • anticoagulant shall mean a compound which reduces the rate of blood coagulation as measured in a kaolin- or thromboplastin-induced clotting assay system.
  • the novel proteins of the present invention are expected to have therapeutic value as anti- inflammatory agents.
  • Inflammation involves the reaction of living tissue to infection or injury, normally resulting in healing and the restoration of tissue structure and function. Inflammation also involves a complex set of responses which neutralize and remove pathogens and lead to the repair of the affected area. Symptoms of inflammation include pain, heat, redness, swelling, and dysfunction. Vascular dilation occurs, together with exudation of fluid into the surrounding tissue.
  • inflammation may be generally regarded as a defensive mechanism, it can in some instances become a disease in itself.
  • Such chronic conditions as arthritis are believed to result from uncontrolled chronic inflamma ⁇ tion.
  • the inflammation reaction results in damage to tissue, which in turn results in increased inflam ⁇ mation. This process usually results in the formation of scar tissue.
  • bursitis are also the result of inflammation, and often lead to severe pain and inhibition of function.
  • glucocorticoids include aspirin and glucocorticoids. These drugs appear to work by inhibiting the production of prostaglandins, which have been implicated as mediators of inflammation. It is believed that the glucocorticoids stimulate the production of lipocortins, which inhibit the action of phospholipase A2 on phospholipids. The release of arachidonic acid from phospholipids by phospholipase A2 is necessary for the synthesis of the prostaglandins. The novel proteins of the present invention bind to phospholipids, thereby blocking the production of arachidonic acid.
  • reducing inflammation shall mean the inhibition, in vivo, of the inflammatory process. Although the physiological mechanisms of this process are not completely understood and are in some instances inferred from _in vitro observations, reduced inflammation will result in a reduction in pain and swelling in the affected site, together with at least partial restoration of normal function.
  • the proteins described herein may be isolated from a variety of biological fluids, including aqueous * extracts of highly vascularized human tissues, including placenta, brain, lung, heart and liver.
  • a particularly preferred tissue source is human placenta.
  • the tissue is chopped and the pieces are homogenized, for example, in a blender or mixer, in the presence of an appropriate buffer (pH 5 to 9, preferably containing a metal chelating agent) .
  • the homogenate is then filtered to remove tissue fragments, and the filtrate is centrifuged. The supernatant (aqueous extract) is then removed.
  • Other biological fluids which may be used as sources of these proteins include cell lysates and culture media from cells which produce the protein(s), including cells containing DNA constructs encoding the protein(s).
  • the biological fluid is first fractionated by adding saturated ammonium sulfate solution or solid ammonium sulfate to approximately 20% to 50% of saturation, preferably about 40% of saturation, to form a first precipitate.
  • the first precipitate is separated from the supernatant by centrifugation, and the supernatant is retained.
  • Ammonium sulfate is added to the supernatant to at least about 60% of saturation, preferably about 80% of saturation, to form a second precipitate.
  • the second precipitate is isolated by centrifugation and dissolved in a suitable buffer to form a solution.
  • the buffer is preferably neutral or slightly basic (pH 7 to 9) and will contain about 10 to ,75 mM salt (NaCl, KCl, etc.) and further containing about 0.5 mM-5 mM EDTA.
  • a particularly preferred buffer in this regard is 50 mM Tris-HCl, pH 7.9, containing 50 mM NaCl and 1 M EDTA.
  • the salt concentration of the solution is then reduced, preferably by dialysis in the same buffer, such that the resulting material can be fractionated by anion-exchange chromatography.
  • the material is applied to an anion- exchange chromatography column and fractionated by elution with a pH 7 to 9 buffer containing a salt- gradient, preferably about 50-500 mM salt concentration, to produce adsorbed and non-adsorbed fractions.
  • a salt- gradient preferably about 50-500 mM salt concentration
  • Preferred anion- exchange chromatography media include DEAE-Sephadex, DEAE-cellulose and DEAE-Sepharose, with DEAE-Sepharose being particularly preferred.
  • the resulting adsorbed and non-adsorbed fractions may then be concentrated to facilitate further purification.
  • Preferred methods of concentration include ammonium sulfate precipitation and polyethylene glycol precipitation.
  • the adsorbed fraction or the concentrated adsorbed fraction is then further fractionated by gel filtration to produce an enriched fraction.
  • Preferred gel filtration media include Sephadex G-75 and G-100.
  • the enriched fractions are then treated to reduce the salt concentration, for example, by dialysis against a low pH buffer (pH 4.0 to 6.0), to permit further fractiona- tion by cation-exchange chromatography.
  • the resulting samples are fractionated by cation-exchange chromatography, preferably on a column of CM-Sephadex, SP-Sephadex, CM-cellulose or Mono-S, using a low pH buffer containing salt.
  • purification is monitored by assaying the various fractions for protein content (e.g., by absorbance at 280 n or by polyacrylamide gel electrophoresis) and for anticoagulant activity (e.g., by standard kaolin- or thromboplastin- induced clotting assays) . Fractions containing anticoagulant activity are pooled for further purification or use in compositions described herein.
  • a metal chelating agent such as EDTA, preferably about 0.5-5 mM EDTA.
  • Two anticoagulant proteins were isolated from the adsorbed fraction from the anion-exchange chromatography. One of these proteins was designated PAP-I, and it was subsequently found to have a molecular weight of about 35,847 by amino acid composition. A second anticoagulant protein, with an apparent molecular weight of about 70,000, was also found in the adsorbed fraction. This protein did not react with an antibody against PAP-I.
  • the non-adsorbed fraction from the anion-exchange chromatography is treated to reduce the salt concentration and fractionated by cation-exchange chromatography as described above. In some instances it may be preferable to enrich the material by gel filtration prior to the cation-exchange chromatography step. Fractions obtained by cation-exchange chromatography are further purified by gel filtration, for example on Sephadex G-75. Additional purification may be obtained using high performance liquid chromatography (HPLC) . In this way three proteins were isolated from the non-adsorbed anion-exchange chromatography fraction. These proteins were designated PAP-II, PAP-III, and PAP-IV. Subsequent analysis showed that PAP-IV is a cleavage product of lipocortin II. These results indicate that at least five different proteins belonging to the lipocortin family are present in the EDTA extract of human placenta.
  • novel proteins of the present invention may also be produced by expressing cloned DNA sequences in recombinant cells.
  • a cDNA sequence encoding one representative protein is disclosed herein. This cDNA was isolated from a human placenta cDNA expression library using an affinity-purified antibody to obtain a cDNA fragment, followed by re-screening of the library with the cloned cDNA fragment. Additional methods of cDNA cloning are also suitable; see, for example, Maniatis et al., eds. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1982).
  • the DNA sequence encoding the anticoagulant and anti-inflammatory protein is inserted into a suitable expression vector.
  • Expression vectors useful in this regard will contain a transcription promoter operably linked to the DNA sequence to be expressed. It is preferred that the vectors also include a transcription terminator. Depending on the particular host cell selected, expression vectors may also contain an origin of replication, enhancer sequences, and other nucleotide sequences which regulate or enhance expression levels. Selectable markers, sequences which provide for the selection and maintenance of the vector in the host cell, may also be provided in the expression vector, although in some cases a selectable marker may be introduced into the host cell on a separate vector. Suitable expression vectors may be derived from plasmids or viruses, or may contain elements of both. Selection of the appropriate elements and construction of vectors is within the ordinary level of skill in the genetic engineering art.
  • a particularly preferred host cell is the yeast Saccharomyces cerevisiae, although other fungal cells, bacteria, and cells from multicellular organisms may also be used.
  • S_. cerevisiae may be cultured in relatively simple media, is inexpensive to culture, and can be made to produce large amounts of foreign protein cytoplasmically. This is particularly advantageous in the case of proteins which do not require disulfide bonding or glycosylation for their activity.
  • To isolate a cytoplasmically produced protein the cells are lysed, cell debris is removed, gener ⁇ ally by centrifugation, and the resulting supernatant is fractionated by conventional chemical methods. Purifica ⁇ tion processes which may be employed include salt fractiona- tion, ion-exchange chromatography, affinity chromatography, and high-performance liquid chromatography.
  • Suitable expression vectors include YRp7 (Struhl et al., Proc. Natl. Acad. 5ci. USA 76: 1035-1039, 1979), YEpl3 (Broach et al., Gene 8 : 121-133, 1979), pJDB248 and pJDB219 (Beggs, ibid. ) , and derivatives thereof.
  • Such vectors will generally include a selectable marker.
  • a defective selectable marker such as the leu2-d gene of Beggs (ibid.
  • yeast expression vectors include promoters from yeast glycolytic genes (Hitzeman et et al., J. Biol. Chem. 255: 12073-12080, 1980; Alber and Kawasaki, J. Mol. Appl. Genet. 1: 419-434, 1982; and Kawasaki, U.S. Patent No. 4,599,311) or alcohol dehydrogen- ase genes, particularly the ADH2-4c promoter (also known as "ADR3-4c"; see Russell et al.. Nature 304: 652-654, 1983).
  • a transcription termination signal such as the TPIl terminator
  • a transcription termination signal such as the TPIl terminator
  • a signal sequence preferably from a yeast gene encoding a secreted protein, may be joined to the coding sequence for the protein of interest.
  • Preferred signal sequences include those of the alpha factor gene (Kurjan et al., U.S. Patent No. 4,546,082) and the BAR1 gene (MacKay et al., U.S. Patent No. 4,613,572).
  • Preferred prokaryotic host cells for use in carry- ing out the present invention are strains of the bacteria Escherichia coli, although Bacillus and other genera are also useful. Techniques for transforming these hosts and expressing foreign genes cloned in them are well known in the art (see, e.g. , Maniatis et al. , ibid.). Vectors used for expressing foreign genes in bacterial hosts will generally contain a selectable marker, such as a gene for antibiotic resistance, and a promoter which functions in the host cell. Appropriate promoters include the trp (Nichols and Yanofsky, Meth. Enzymol.
  • Plasmids useful for transforming bacteria include pBR322 (Bolivar et al. , Gene 2_: 95-113, 1977), the pUC plasmids (Messing, Meth. Enzymol. 101: 20-77, 1983; Vieira and Messing, Gene 19: 259-268, 1982), pCQV2 (Queen, J. Mol. Appl. Genet. 2_: 1-10, 1983), and derivatives thereof. Plasmids may contain both viral and bacterial elements.
  • Expression vectors for use in mammalian cells will comprise a promoter capable of directing the transcription of a cloned gene or cDNA introduced into a mammalian cell.
  • promoters are the mouse metallothionein-1 (MT-1) promoter (Palmiter et al., Science 222: 809-814, 1983), or the major late promoter of adenovirus 2.
  • MT-1 mouse metallothionein-1
  • the polyadenylation signal may be that of the cloned gene, or may be derived from a heterologous gene.
  • Cloned DNA sequences may then be introduced into cultured mammalian cells by, for example, calcium phosphate- mediated transfection (Wigler et al.. Cell 14: 725, 1978; Corsaro and Pearson, Somat. Cell Genet. l_ ⁇ 603, 1981; Graham and Van der Eb, Virol. 52: 456, 1973) or electroporation (Neumann et al., EMBO J. 1 : 841-845, 1982).
  • a gene that confers a selectable pheno- type is generally introduced into the cells along with the gene of interest.
  • select ⁇ able markers include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. Selectable markers may be introduced into the cell on a separate expression vector at the same time as the gene of interest, or they may be introduced on the same expression vector.
  • the copy number of the integrated gene sequence may be increased through amplification by using certain selectable markers (e.g. , dihydrofolate reductase, which confers resistance to methotrexate) .
  • selectable marker e.g. , dihydrofolate reductase, which confers resistance to methotrexate
  • the selectable marker is introduced into the cells along with the gene of interest, and drug selection pressure is applied.
  • the drug concentration is then increased in a stepwise manner, with selection of resistant cells at each step. By selecting for increased copy number of cloned sequences, expression levels may be substantially elevated.
  • the selected host cells are grown in an appropriate culture medium, and the protein may be isolated as described above.
  • Example 1 Anticoagulant Assay Method Reagents: The complete content of one vial of rabbit brain cephalin (Sigma) was uniformly suspended in 100 ml of saline and used as a source of phospholipid. Equal volumes of phospholipid suspension and 0.033 M CaCl2 were mixed before assay. Acid-washed kaolin (Fischer) was suspended in saline at 50 mg/ml.
  • a fresh human placenta was obtained from a local hospital and the umbilical cord and amniotic membrane were removed.
  • An aqueous extract was prepared from the placenta by first cutting it into small pieces with a meat chopper and then soaking it in 2 liters of cold 50 mM Tris-HCl buffer, pH 7.9, containing 50 mM NaCl and 1 mM EDTA (buffer A) to remove the blood. The buffer was drained and the washing was repeated twice with the same volume of buffer.
  • the placenta was then transferred to a Waring blender and homogenized for 1 minute with 1 liter of cold buffer A containing 5 mM EDTA and 5 mM benzamidine.
  • the homogenate was filtered through a sheet of gauze. Tissue remaining on the gauze was put into the blender and homogenization was repeated with 1 liter of buffer. The resulting homogenate was then filtered, and the two filtrates were combined.
  • the dialyzed sample was transferred to a 2-liter plastic beaker and stirred for 2 hours with 350 ml of DEAE- Sepharose gel that had been equilibrated with buffer A. - After the DEAE-Sepharose gel was settled, the supernatant was decanted. The gel was then poured into a plastic column (4.5 x 23 cm) and the column was washed with 2 liters of the same buffer. Adsorbed proteins were then eluted with a linear gradient formed by 1 liter of buffer A and 1 liter of 500 mM NaCl in 50 M Tris-HCl, pH 7.9 containing 1 mM EDTA.
  • Fractions were assayed for anticoagulant activity by the method described in Example I, and the active fractions associated with the descending edge of the first protein peak were pooled. A typical elution profile is shown in Figure 1. The pooled enriched fractions are indicated by the bar. To concentrate the enriched fraction, ammonium sulfate was added to 80% of saturation and the precipitate was collected by centrifugation. The precipitate was then dissolved in 50 ml of 50 mM Tris-HCl buffer, pH 7.9, containing 0.2 M NaCl and 1 mM EDTA (buffer B) and dialyzed for 2 hours against 2 liters of buffer B.
  • buffer B buffer B
  • the dialyzed sample was then applied to a column (5.5 x 100 cm) of Sephadex G-75 that had been equilibrated with buffer B.
  • the column was eluted with buffer B at a flow rate of approximately 100 ml/h.
  • the fractions which eluted after a major protein peak contained the anticoagulant activity.
  • the enriched active fractions (indicated by the bar in Figure 2) were pooled and dialyzed against 2 liters of 25 mM Na-acetate buffer, pH 5.2, containing 0.5 mM EDTA (acetate buffer) with two changes of buffer to reduce the salt concentration.
  • the dialyzed sample was applied to a Mono-S column connected to a FPLC system (Pharmacia) , and the adsorbed proteins were eluted with a linear gradient composed of buffer C (0.0 M NaCl in the acetate buffer) and buffer D (0.5 M NaCl in the acetate buffer). Elution was performed by a flow rate of 0.5 ml/min with a 0.67% increment of buffer D per minute. A major protein peak eluting at approximately 12% buffer D was collected (Figure 3). This fraction contained homogeneous protein having anticoagulant activity. Approximately 20-25 mg of purified protein were obtained from one human placenta by this procedure.
  • the purified PAP-I protein migrates as a single band (33,500 daltons) on SDS-polyacrylamide gel electrophoresis under reducing conditions ( Figure 4) .
  • the protein migrates as two bands of approximately 74,000 (40%) and 37,000 daltons (60%) on a non-reducing gel.
  • the protein also gives a single band by disc gel electrophoresis.
  • the molecular weight of the purified PAP-I was estimated to be 36,500 by the Weber SDS polyacrylamide gel system (Weber and Osborn, J. Biol. Che . 244: 4406, 1969).
  • the amino acid composition of a 24-hour acid hydrolysate of the protein was determined by a Waters picotag system and is shown in Table 1.
  • the protein is composed of approximately 319 amino acid residues/molecule, plus one acetyl group, indicating the presence of a blocked amino acid residue at the amino terminus of the protein.
  • Purified PAP-I (4 mg) was digested for 24 hours at room temperature in 1 ml of 2% cyanogen bromide/70% formic acid and the resultant peptides were separated by a peptide reversed phase column (Pharmacia).
  • the cyanogen bromide digest was dissolved in 1 ml of 0.1% aqueous trifluoroacetic acid (buffer E) and applied to the peptide reverse phase column.
  • the peptides were eluted by a linear gradient composed of buffer E and buffer F (0.1% trifluoroacetic acid in 80% acetonitrile) . Elution was performed by a flow rate of 1.5 ml/min with 2% increment/min of buffer F in buffer E.
  • a blocked peptide that originated from the NH2 ⁇ terminus was digested with lysine endopeptidase and the resulting peptides were separated by reversed phase HPLC column.
  • One of the peptides of which the NH2 ⁇ terminus was blocked had a composition of one mole each of Glu, Gly, Arg, Thr, Ala, Val and Leu. This composition agreed with the 5' end sequence of seven residues deduced from the cDNA sequence.
  • the NH2 ⁇ terminal sequence of PAP-I was found to be acetyl-Ala-Gln-Val-Leu-Arg-Gly-Thr.
  • Amino acid residues are designated within Table 2 by single letter code as follows: A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, ethionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine; (X) indicates any unknown residue.
  • Kaolin-induced clotting activites were assayed by incubating 20 ⁇ l of kaolin (50 mg/10 ml), 20 ⁇ l of pooled normal human plasma and 10 ⁇ l of purified protein for 10 minutes at 37°C. Forty ⁇ l of CaCl2 ⁇ phospholipid was then added and clotting times were determined. Thromboplastin-induced clotting times were determined by the same procedure as the kaolin-induced assay except that 20 ⁇ l of human brain thromboplastin was used. The effects of the purified protein on partial thromboplastin and kaolin-induced clotting times are shown in Table 3. Addition of 300 ng of the purified protein increased the partial thromboplastin time from 70 to 160 seconds and addition of 100 ng of the protein increased the kaolin-induced clotting time from 77 to 130 seconds.
  • the proteins described herein also inhibit the activation of prothrombin in normal human plasma by a complex of factor Xa-phospholipid-Ca ++ .
  • Factor Xa 5 ng
  • the purified PAP-I protein 50 ng
  • Normal human plasma 20 ⁇ l
  • 40 ⁇ l of phospholipid/CaCl2 were then added to this preincubation mixture and the clotting time was determined.
  • the clotting time with the purified protein was over 300 seconds, while the clotting time of a control sample without the anti ⁇ coagulant protein was 43 seconds.
  • the purified PAP-I protein was shown to readily bind to phospholipid vesicles. Binding of PAP-I to phospholipid vesicles was measured by gel filtration of a PAP-I/phospholipid mixture.
  • Phospholipid vesicles were prepared as follows: 0.4 mg of egg yolk phosphatidyl choline (PC) and 0.1 mg of bovine brain phosphatidyl serine (PS) in chloroform were mixed in a test tube, and the organic solvent was evaporated under gas. The dried lipid was suspended in 0.5 mL of 50 mM Tris, pH 7.4, containing 0.15 M NaCl, and the suspension was sonicated twice for 15 seconds (s) .
  • PC egg yolk phosphatidyl choline
  • PS bovine brain phosphatidyl serine
  • a complete binding mixture contained in 220 ⁇ L of buffer A 0.1 mg of phospholipid vesicles, 5 ⁇ g of 125 ⁇ -PAP (total 2.5 X 10 5 cmp), BSA (1 mg/mL) , and 5 mM CaCl2 « This mixture was applied to a column (0.7 x 14 cm) of Sepharose 4B that had been equilibrated with 50 mM Tris-HCl, pH 8.9, containing 50 mM NaCl, and the column was run with the same buffer. The eluate was collected in 0.5 ml fractions and the radioactivity was detected in the void volume fraction (tubes 5 and 6), indicating the binding of the anticoagulant to phospholipid vesicles. In the absence of phospholipid or CaCl2 in the reaction mixture, the radioactivity was found in the later fractions (tubes 9 to 11) . Maximum binding requires the presence of calcium ions in the reaction mixture.
  • PAP-I does not inhibit amidase activity of thrombin or factor Xa, nor does it bind to purified factor Xa.
  • the amidase activities of factor Xa and thrombin were measured with Boc-Ile-Glu-Gly-Arg-MCA ( ethylcoumarin) and Boc-Val-Pro-Arg-MCA, respectively.
  • Five ng of factor Xa or thrombin were incubated with 0.5 M of the substrates in the presence or absence of 0.1 ⁇ g of PAP-I.
  • the amidase activity was determined by the increase of fluorescence (emission 380 nm, excitation 460 nm) .
  • PAP-I had no effect on the amidase activity of either thrombin or factor Xa.
  • factor Xa Four ug of factor Xa was mixed with 0.1 ⁇ g of PAP-I (total reaction volume of 20 ⁇ l) and applied to a gel filtration column of TSK 3000 (Toyo Soda) that had been equilibrated with 50 mM Tris-HCl, pH 7.9, containing 50 mM NaCl. Two peaks were found in the eluates. These elution positions corresponded to those of factor Xa and PAP-I. No protein peak was found at the position prior to factor Xa. This result shows the failure of the formation of a protein/protein complex between PAP-I and factor Xa.
  • the DEAE-Sepharose effluent fraction from Example 2 was used as a starting, material for the preparation of PAP-II, -III and -IV.
  • This fraction (2 liters) was dialyzed against 10 liters of 50 mM sodium acetate buffer, pH 5.2, with two changes of buffer. The dialyzate was then stirred for 30 minutes with 350 ml of CM-Sephadex that had been equilibrated with the acetate buffer. The resin was settled and the supernatant was decanted and discarded. The resin slurry was then poured into a plastic column (4.5 x 30 cm) .
  • the precipitates were dissolved in a minimum volume of 50 M Tris-HCl buffer, pH 7.9, containing 0.2 M
  • the anticoagulant activities were associated with the shoulder peaks.
  • the active fractions from each of the gel filtration columns were pooled and dialyzed against 25 mM sodium acetate buffer, pH 5.2, containing 0.5 mM EDTA. The dialyzed samples were then applied to a Mono
  • PAP-I SDS-polyacrylamide gel electrophoresis patterns of PAP-I, PAP-II, PAP-III and PAP-IV are shown in Figure 4. All four of the proteins were purified to homogeneity.
  • the estimated molecular weights of PAP-I, -II, -III, and -IV are 32,000, 34,000, 35,000 and 36,000, respectively.
  • the molecular weight of PAP-I was determined to be 35,847 from the amino acid composition of the completed sequence, indicating a potential experimental error of about 4000 Da in the estimated molecular weights.
  • PAP-II and PAP-III were digested with cyanogen bromide and the resulting fragments were separated by a HPLC system using a C3 reversed phase column. Amino acid sequence analyses were performed with six fragments from PAP-II, five fragments from PAP-III, and two fragments from PAP-IV. Approximately 180 residues from PAP-II, 130 residues from PAP-III, and 50 residues from PAP-IV were determined. Alignment of these sequences with PAP-I and lipocortin-1 is shown in Figure 5. Amino-termini of PAP-I and PAP-III are blocked. Amino-termini of PAP-II and PAP-IV are not blocked.
  • proteins may be isolated by the above processes, or by variations of the above processes as previously described.
  • minor variations in protein structure may exist due to genetic polymorphisms or cell-mediated modifications of the proteins or their precursors.
  • amino acid sequence of a protein may be modified by genetic techniques to produce proteins with slightly altered biological activities.
  • a human placenta cDNA library (Clontech) was screened using affinity-purified antibody against PAP-I according to the methods of Young and Davis (Proc. Natl. Acad. Sci. USA 80: 1194-1198, 1983) and Foster and Davie Proc. Natl. Acad. Sci. USA 81: 4766-4770, 1984). Twelve positive clones were obtained from 5 X 10 ⁇ reco binants and were then plaque-purified. Sequence analysis of the larg ⁇ est clone (1.5 kb insert) showed that this clone contained an open reading frame sequence coding for PAP-I starting from residue 38 and extending to the 3 1 non-coding region containing the poly(A) tail.
  • the original library was then re-screened using this clone as a hybridization probe.
  • the probe was labeled by the method of Maniatis et al. (Proc. Natl. Acad. Sci. USA 72: 1184-1188, 1975). Filters were washed with 2 X SSC buffer (8.2 g of Na-citrate pH 7.0 and 17.5 g of NaCl/liter) containing 0.5% SDS at 60°C for 1 hour. Twenty-four clones were then obtained and plaque-purified. Positive clones were subcloned into Ml3mpl8 or Ml3mpl9 for sequence analysis using the dideoxy-35s method of Sanger et al. (Proc. Natl. Acad. Sci.
  • Example 5 Expression of PAP-I in Yeast
  • the PAP-I cDNA was linked to the ADH2-4c promoter and the TPIl terminator.
  • This expression unit was inserted into several yeast expression vectors and the vectors were used to transform selected yeast strains.
  • An ADH2-4c promoter was constructed by joining the downstream portion of the wild-type ADH2 (alcohol dehydrogenase II) promoter to the upstream portion of the ADH2-4c promoter described by Russell et al. (Nature 304: 652-654, 1983). The upstream sequences of the ADH2-4c promoter are responsible for its enhanced function. Construction of this promoter is illustrated in Figure 9. The 2.2 kb Bam HI fragment containing the wild-type ADH2 structural gene and the 5 1 flanking sequences from pBR322-ADR2-BSa (Williamson et al..
  • the replicative form of the mutagenized phage was made and cut with Bam HI and Eco RI to isolate the 1.2 kb promoter fragment. This fragment was ligated into pUC13 which had been linearized with Bam HI and Eco RI to generate plasmid p237-Wt.
  • p237-wt promoter to the "promoter up" mutant ADH2-4c promoter
  • a 1.1 kb Bam Hl-Sph I fragment from YRp7-ADR3-4c (Russell et al., ibid.) containing the alterations found to influence promoter function was subcloned into the vector fragment of p237-Wt which had been cut with Bam HI and Sph I.
  • the resulting plasmid was designated p237-4c ( Figure 9).
  • Plasmid pAT-1 comprises the expression unit of the ADH2 promoter from p237-Wt and an ⁇ -1-antitrypsin cDNA-TPIl terminator sequence. These sequences were inserted into a portion of the vector pCPOT. (Plasmid pCPOT has been deposited with ATCC as an E ⁇ coli strain HB101 transformant and has been assigned accession number 39685.
  • Plasmid pCPOT was cut with Bam HI and Sal I to isolate the approximately 10 kb linear vector fragment.
  • the 1.2 kb ADH2 promoter fragment was isolated from p237-WT as a Bam HI-Eco RI fragment and ligated with, the 1.5 kb ⁇ -1-antitrypsin cDNA-T Il terminator fragment (Eco Rl-Xho I) and the linearized pCPOT in a three-part ligation to yield a plasmid designated pAT-1.
  • Plasmid pAT-1 contained three extra amino acid codons between the ADH2 translation start codon and the first amino acid codon for the mature form of AAT. These three codons were removed by site-specific in vitro mutagenesis. Plasmid pAT-1 was cut with Sph I and Bam HI to isolate the 190 bp ADH2 promoter fragment. This fragment was ligated into M13mpl8 which had been linearized with Bam HI and Sph I.
  • the resulting construction was subjected to in vitro mutagenesis using ZC411 ( 5 'TAATACACAATGGAGGATCCC 3 ' ) as the mutagenic primer and ZC87 as the second primer to fuse the ADH2 translation start signal to the first codon of mature ⁇ -1-antitrypsin. Positive clones were confirmed by dideoxy sequencing from -170 bp from the ATG through the fusion point.
  • the 175 bp Sph I-Eco RI mutagenized promoter fragment was ligated into pUC19 linearized with Sph I and Eco RI.
  • the resultant plasmid comprising the 3' most 170 bp of the ADH2 promoter and the ADH2 translation start fused to the first amino acid of the mature form of AAT in vector pUC19, was designated p411.
  • the 5 1 most sequence of the ADH2-4£ promoter containing the alterations found by Russell et al. (supra. ) to influence promoter function, was added to the promoter fragment present in plasmid p411.
  • Plasmid p411 was digested with Sph I and Eco RI to isolate the 175 bp promoter fragment.
  • Plasmid p237-4 c was cut with Eco RI and Sph I to isolate the 3.71 kb fragment comprising pUC vector sequences and the 5* most promoter sequence that confers the "promoter-up" phenotype.
  • the 175 bp promoter fragment from p411 was ligated into the p237-4 c vector fragment.
  • the ADH2 promoter from plasmid pAT-1 was modified to create a "universal" promoter by removing the ADH2 translation start site and the pUC18 polylinker sequences found in pAT-1. Plasmid pAT-1 was cut with Sph I and Bam HI to isolate the 190 bp partial ADH2 promoter fragment. This fragment was ligated into M13mpl8 linearized with Bam HI and Sph I.
  • the resulting construction was subjected to in vitro mutagenesis using ZC410 ( 5 'CG AATACAGAATTCCCGGG 3 ' ) as the mutagenic primer and ZC87 as the second primer to replace the ADH2 translation start signal and pUC18 polylinker sequences with a single Eco RI site fused to the M13mpl8 polylinker at the Sma I site. Positive clones were confirmed by dideoxy sequencing through the fusion point. For ease of manipulation, the mutagenized partial ADH2 promoter fragment was subcloned as a 175 bp Sph I-Eco RI fragment into pUC19 which had been linearized with Sph I and Eco RI.
  • the resulting plasmid contained the 3'-most 175 bp of the ADH2 promoter.
  • the ADH2-4c promoter was then modified to contain this 3' sequence by combining the p410ES promoter fragment (Sph I-Eco RI) with the 1.1 kb Bam Hl-Sph I ADH2-4c promoter fragment from p237-4c.
  • the two promoter fragments were joined with Bam HI, Eco RI cut pUC13 in a three-part ligation.
  • the resultant plasmid confirmed by restriction analysis, contained the complete ADH2-4c promoter mutagenized at the 3* end to place an Eco RI site in place of the translation start codon.
  • This plasmid was designated p410-4c ( Figure 9).
  • the PAP-I cDNA was then joined to the ADH2-4c promoter.
  • Plasmid pAP1.7 comprising the 1.7 kb cDNA in ⁇ UC18, was cut with Nco I and Bam HI and the linearized plasmid was isolated through two rounds of gel purification.
  • the ADH2-4c promoter was functionally linked to the, 5' end of the PAP-I cDNA through an adaptor having the following structure:
  • Plasmid pCPOT was cleaved with Sph I and Bam HI to remove 750 bp of 2 micron and pBR322 sequences.
  • the linearized vector was then joined to a 186 bp Sph I-Bam HI fragment derived from the pBR322 tetracycline resistance gene.
  • the resulting plasmid, designated pDPOT ( Figure 10) was cut with Bam HI and treated with calf intestinal phosphatase.
  • Plasmid pPRl was digested completely with Bam HI and partially with Sst I and the -2.1 kb promoter + PAP-I fragment was recovered.
  • the yeast TPIl terminator fragment was obtained from plasmid pFGl (Alber and Kawasaki, J. Mol. Appl. Genet. 1: 419-434, 1982; see Figure 11). It encompasses the region from the penultimate amino acid codon of the TPIl gene to the Eco RI site approximately 700 base pairs downstream. A Bam HI site was substituted for this unique Eco RI site of pFGI by first cutting the plasmid with Eco RI, then blunting the ends with DNA poly erase I (Klenow f agment) , adding synthetic Bam HI linkers (CGGATCCA) , and re-ligating to produce plasmid pl36.
  • the TPIl terminator was then excised from pl36 as a Xba I-Bam HI fragment. This fragment was ligated into YEpl3 (Broach et al., Gene ⁇ 3: 121, 1979) which had been linearized with Xba I and Bam HI. The resulting plasmid is known as p213.
  • the Hind III site was then removed from the TPIl terminator region of p213 by digesting the plasmid with Hind III, blunting the resultant termini with DNA polymerase I (Klenow fragment) , and recircularizing the linear molecule using T4 DNA ligase. The resulting plasmid was designated p270 ( Figure 11).
  • p270 may be constructed by digesting plasmid pM220 (deposited with American Type Culture Collection as an E_ ; _ coli RRl transformant, accession number 39853) with Xba I and Bam HI, purifying the TPIl terminator fragment ( ⁇ 700 bp) and inserting this fragment into Xba I, Bam HI digested YE ⁇ l3.
  • the TPIl terminator was removed from plasmid p270 as a Xba I-Bam HI fragment. This fragment was cloned into pUC19 along with another fragment containing the TPIl promoter fused to the CAT (chloramphenicol acetyl transferase) gene to obtain a TPIl terminator fragment with an Eco RV end. The resultant plasmid was designated pCAT ( Figure 11). The TPIl terminator was then cut from pCAT as an Eco RV-Bam HI fragment and cloned into pIC19H (Marsh et al., Gene 32: 481-486, 1984) which had been cut with the same enzymes, to obtain pTTl ( Figure 11).
  • Plasmid pTTl was digested with Sst I and Bam HI and the -800 bp TPIl terminator fragment was recovered. The three fragments (Bam Hl-cut pDPOT, Bam Hl-Sst I promoter + PAP-I and Sst I-Bam HI terminator) were then joined ( Figure 10). Two different expression vectors with opposite expression unit orientations were obtained. These vectors were designated pD3 and pD4. Plasmid pD4 was transformed into S_ ; _ cerevisiae ho ozygous diploid strain ZM118 (a/ ⁇ pep4: :URA3 tpil: :URA3 leu2 ⁇ ura3 barl) . The transformants were grown in Medium B (2% Bacto Yeast Extract, 0.5% ammonium sulfate with 2% glucose as the carbon source) for 48 hours at 30°C.
  • Medium B 2% Bacto Yeast Extract, 0.5% ammonium sulfate with
  • the cultures were centrifuged to pellet the cells and the spent medium was discarded.
  • the cells were pelleted and washed with distilled water.
  • the washed pellets were frozen at -80°C before being assayed.
  • Crude glass bead lysates were made of the frozen cell pellets.
  • the washed cell pellets were thawed on ice and diluted in an equal volume of phosphate-buffered saline (PBS).
  • Glass beads 450-500 um were added to one half the total volume.
  • the cells were lysed by vortexing the mixture at full speed for one minute, three times, with the samples cooled on ice between vortex bursts. Larger samples of 50 ml or more were treated in the same manner but lysed in a Bead Beater (Biospec Products, Bartlesville, Oklahoma) and cooled in an ethanol-dry ice bath between bursts.
  • Bead Beater Biospec Products, Bartlesville, Oklahoma
  • the liquid was removed from the tubes with - a pasteur pipet and transferred to a microfuge tube.
  • the glass beads were washed once in the original volume of PBS.
  • the beads were vortexed one minute and the liquid was removed by pasteur pipet and pooled with the original lysate.
  • the lysates were then centrifuged in an Eppendorf microfuge (Brinkmann, Westbury, New York) at top speed for five minutes. The supernatants were carefully removed and assayed for anticoagulant activity essentially as described in Example 1.
  • the assay demonstrated that clotting was inhibited by the cleared lysates.
  • Yeast-produced PAP-I was purified and the anticoagulant activity was compared to that of placental PAP-I.
  • Approximately 900 g (wet weight) of transformed S. cerevisiae cells were lysed in a Bead Beater with three 1 minute bursts in PBS. The beads were washed with 100 ml PBS and the lysate was centrifuged in an HB4 rotor (Sorval) at 4°C for 60 minutes at 10,000 rp . The supernatant was removed. Ammonium sulfate was added to the supernatant to 40% of saturation, and the mixture was incubated at 4°C for at least 1 hour. The mixture was then centrifuged as above and the pellet was discarded.
  • the supernatant was dialyzed against 50 ml Tris HC1 pH 7.9 containing 50 mM NaCl and 1 mM EDTA. The supernatant was then passed over a DEAE-Sepharose fast flow column (Pharmacia, Piscataway, NJ) using a gel volume of approximately 1 ml per 25 mg of protein. The column was washed in 50 mM Tris HC1 pH 7.9, 50 mM NaCl and 1 mM EDTA and eluted with a gradient of the same buffer and 50 mM Tris HCl, pH 7.9, containing 1 M NaCl and 1 mM EDTA. PAP-I eluted at approximately 0.2 M NaCl.
  • Fractions from the DEAE-Sepharose column were assayed by gel electrophoresis. Peak fractions were precipitated by the addition of ammonium sulfate to 70% saturation. The mixtures were incubated at 4°C for at least 1 hour, then centrifuged. The pellets were resuspended in 50 mM Tris, pH 7.9, containing 0.2 M NaCl and 1 mM EDTA, using a minimal volume of buffer. The resulting colutions were passed over a Sephacryl S-200 (Pharmacia) column. Fractions from the S-200 column were assayed by gel electrophoresis. Peak fractions were dialyzed against 10 M sodium acetate, pH 5.2.
  • the dialyzed fractions were passed over an S-Sepharose (Pharmacia) fast-flow column and washed in the same buffer.
  • the column was eluted with a gradient of the same buffer and 10 mM sodium acetate, pH 5.2, plus 1 M NaCl containing 0.5 mM EDTA.
  • 100 ⁇ l of purified protein was combined with 100 ⁇ l each of kaolin (acid washed; Fisher Scientific Co., Pittsburgh, PA; 5 mg/ml in IBS [0.05 M imidazole pH 7.35, 0.1 M NaCl, 0.02% NaN 3 ]) and human brain cephalin (diluted 1:250 in IBS).
  • PAP-I was administered to rabbits to test its antithrombotic effect and overall effects on the general condition of the animals.
  • the antithrombotic effect of PAP-I was tested in a rabbit model essentially as described by Diness et al. (Thromb. Haemostas 55: 410-414, 1986). Briefly, the rabbits were anesthetized by an intravenous bolus injection of sodium pentobarbital via a catheter in a marginal ear vein. Anesthesia was maintained by additional injections of pentobarbital. Both facialis veins were exposed via an incision in the ventral part of the neck and a segment of about one cm close to the jugular vein was isolated between two clamps. The segment was flushed with Aethoxysklerol (5 mg/ml) , thus producing endothelial damage.
  • the segment was flushed with saline, the clamps were removed, and the blood was allowed to flow through the segment for one minute. Total stasis was then produced by a ligature at the proximal end of the segment. Thirty minutes after the injection of Aethoxysklerol, the veins were removed and inspected for the presence of thrombi. The thrombi, if any, were placed in preweighed vials and the wet weights were determined.
  • the test compound (0.5 ml of 1.5 mg/ml PAP-I in 50 mM Tris, 50 mM NaCl, pH 7.9) was given to two rabbits immediately after flushing the segment with Aethoxysklerol, i.e., before the clamps were removed.
  • the test compound was injected via an intravenous catheter in the ear which was not used for administration of sodium pentobarbital.
  • Two rabbits were given conventional heparin (0.5 mg/kg) and four rabbits were given saline as controls.
  • a PE-90 catheter was placed in the carotid artery and kept open by a slow infusion of saline. This catheter was also used for blood sampling in rabbits receiving PAP-I.
  • Blood samples (1.8 ml of blood + 0.2 ml of citrate) were taken before and 10, 25, 45, 60, 90 and 120 minutes after administration of PAP-I. The samples were centrifuged at 2000 x g for 10 minutes. Plasma of each sample was divided between two vials and frozen within 30 minutes after blood sampling.
  • Results are presented in Table 5.
  • control rabbits a thrombus was found in all veins (two thrombi per rabbit) .
  • the means and 95% confidence limits were calculated from log values, transferring data into normal distribution. Calculated from log values, the mean of the total weight of thrombi per rabbit in the control group was 20.2 mg and the 95% confidence limits (+2 SD) were 5.0-81.5 mg.
  • the two rabbits receiving PAP-I two small thrombi were found in one rabbit and only one small thrombus in the other. In both cases the total weight of thrombi per rabbit was below the 95% confidence limits of the control group.
  • Conventional heparin 0.5 mg/kg totally prevented thrombus formation in two rabbits.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP88902031A 1987-02-06 1988-02-05 Menschliche proteine mit blutgerinnungs- und entzündungshemmender wirkung Withdrawn EP0300030A1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1178287A 1987-02-06 1987-02-06
US11782 1987-02-06
US5935587A 1987-06-05 1987-06-05
US59355 1987-06-05

Publications (1)

Publication Number Publication Date
EP0300030A1 true EP0300030A1 (de) 1989-01-25

Family

ID=26682778

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88902031A Withdrawn EP0300030A1 (de) 1987-02-06 1988-02-05 Menschliche proteine mit blutgerinnungs- und entzündungshemmender wirkung

Country Status (4)

Country Link
EP (1) EP0300030A1 (de)
JP (1) JPH01502667A (de)
AU (2) AU1299788A (de)
WO (1) WO1988005659A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08840B2 (ja) * 1986-11-14 1996-01-10 興和株式会社 抗ｐｃｉモノクローナル抗体、これを用いた抗ｐｃｉの精製法及び免疫学的測定法
JP2660514B2 (ja) * 1987-02-20 1997-10-08 興和株式会社 抗血液凝固作用を有するポリペプチド
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
DE3737237A1 (de) * 1987-11-03 1989-05-18 Behringwerke Ag Anticoagulatorisches protein pp4-x, seine herstellung und verwendung
US5320950A (en) * 1987-11-03 1994-06-14 Behringwerke Aktiengesellschaft DNA encoding anticoagulative protein PP4-X, and its preparation and use
DE68923107T2 (de) * 1988-02-26 1996-01-18 Biogen Inc DNA-Sequenzen, rekombinante DNA-Moleküle und Verfahren zur Herstellung von Lipocortin III, IV, V, und VI.
EP0339285A3 (de) * 1988-03-31 1989-11-29 RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) Rekombinantes Endonexin II
MX9203460A (es) * 1988-09-12 1992-09-01 Upjohn Co Nuevos analogos cc-1065 que tienen dos subunidades cpi.
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60199819A (ja) * 1984-03-23 1985-10-09 Kowa Co トロンビン結合性物質およびその製法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8805659A1 *

Also Published As

Publication number Publication date
JPH01502667A (ja) 1989-09-14
AU1299788A (en) 1988-08-24
WO1988005659A1 (en) 1988-08-11
AU8891691A (en) 1992-05-14

Similar Documents

Publication Publication Date Title
US4937324A (en) Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
US5312736A (en) Anticoagulant analogues of the tissue factor extrinsic pathway inhibitor (EPI) with reduced affinity for heparin
EP0726953B1 (de) Menschliche proteaseinhibitoren vom kunitztyp
JP3051995B2 (ja) 酸化抵抗性トロンボモジュリン類縁体
EP0268772B1 (de) Expression des biologisch aktiven Faktors XIII
EP0300030A1 (de) Menschliche proteine mit blutgerinnungs- und entzündungshemmender wirkung
AU646633B2 (en) Soluble analogs of thrombomodulin
CA2093575A1 (en) Human antithrombin iii mutant
FI110669B (fi) Menetelmiä luonnosta eristettävissä tai synteettisesti valmistettavissa olevien trombiini-inhibiittorien valmistamiseksi
JPH05506354A (ja) 端が切り取られた軽鎖を有する活性プロテインｃ
JPH0798840B2 (ja) 尿由来の抗血液疑固物質、その製法およびそれを含有する医薬組成物
US6265378B1 (en) Protein Z-dependent protease inhibitor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19890119

17Q First examination report despatched

Effective date: 19910612

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930309